ARS Pharmaceuticals updates corporate presentation; no material new details disclosed

ARS Pharmaceuticals, Inc.

Filed a Form 8-K on March 13, 2023, to furnish an updated corporate presentation.
Presentation highlights neffy as 'first no-needle, no-injection solution' for Type I allergic reactions.
No financial, clinical, or regulatory milestones were reported in the filing or the title slide of Exhibit 99.1.
Presentation is available on the company's website; content beyond the title slide is not provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.